Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism.
- Author:
Sung Hee LIM
1
;
Sook Young WOO
;
Seonwoo KIM
;
Young Hyeh KO
;
Won Seog KIM
;
Seok Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: Diffuse large B-cell lymphoma; Venous thromboembolism; Risk factors; Chemotherapy
- MeSH: B-Lymphocytes*; Cohort Studies; Cross-Sectional Studies*; Cyclophosphamide; Cytokines; Diagnosis; Doxorubicin; Drug Therapy; Follow-Up Studies; Humans; Interleukin-10; Interleukins; Lymphoma, B-Cell*; Multivariate Analysis; Prednisone; Prospective Studies; Risk Factors; Thrombosis; Tumor Burden*; Venous Thromboembolism*; Vincristine
- From:Cancer Research and Treatment 2016;48(1):312-321
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The risk factors for venous thromboembolism (VTE) in diffuse large B-cell lymphoma (DLBCL) are not clear although thrombosis can be associated with host status, tumor burden, and inflammatory activity. We assessed the effect of those factors on VTE in a cross-sectional study of patients enrolled in a prospective cohort study. MATERIALS AND METHODS: We analyzed the occurrence of VTE in 322 patients with newly diagnosed DLBCL who received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) between 2008 and 2011. Serum levels of inflammatory cytokines were measured from serum samples archived at diagnosis. RESULTS: With a median follow-up duration of 41.9 months, VTE was documented in 34 patients (10.6%). A comparison of baseline characteristics indicated the group with VTE had higher percentage of old age, stage III/IV and extranodal involvements than the group without VTE (p < 0.05). Thus, the International Prognostic Index was significantly associated with VTE, but the Khorana score was not. A univariate competing risk factor analysis for VTE revealed that increased levels of inflammatory cytokines such as interleukin (IL)-6 and IL-10 were also associated with VTE (p < 0.05) in addition to host and tumor burden. However, a multivariate analysis showed that two host factors including age (> or = 60 years) and poor performance were independent risk factors for VTE. CONCLUSION: Among potential risk factors for VTE including tumor burden and inflammatory activity, age and performance status had a strong impact on the occurrence of VTE in patients with DLBCL who received R-CHOP.
